

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Check this box to indicate that a
transaction was made pursuant to a
contract, instruction or written plan for
the purchase or sale of equity securities
of the issuer that is intended to satisfy
the affirmative defense conditions of
Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>AH Bio Fund II, L.P.</u> (Last) (First) (Middle) <u>C/O ANDREESSEN HOROWITZ</u> <u>2865 SAND HILL ROAD, SUITE 101</u> (Street) <u>MENLO PARK CA 94025</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Scribe Therapeutics, Inc. [SCTX]</u> Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) <u>07/27/2026</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director ☒ 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person ☒ Form filed by More than One Reporting Person
---	---	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/27/2026		C		2,051,742	A	(1)	2,051,742	I	By AH Bio Fund II, L.P. ⁽²⁾
Common Stock	07/27/2026		C		697,650	A	(1)	697,650	I	By AH Bio Fund III, L.P. ⁽³⁾ (4)
Common Stock	07/27/2026		P		333,333	A	\$15	2,385,075	I	By AH Bio Fund II, L.P. ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	07/27/2026		C			12,150,003	(1)	(1)	Common Stock	2,051,742	\$0	0	I	By AH Bio Fund II, L.P. ⁽²⁾
Series B Preferred Stock	(1)	07/27/2026		C			4,131,344	(1)	(1)	Common Stock	697,650	\$0	0	I	By AH Bio Fund III, L.P. ⁽³⁾ (4)

1. Name and Address of Reporting Person* <u>AH Bio Fund II, L.P.</u> (Last) (First) (Middle) <u>C/O ANDREESSEN HOROWITZ</u> <u>2865 SAND HILL ROAD, SUITE 101</u> (Street) <u>MENLO PARK CA 94025</u> (City) (State) (Zip)	1. Name and Address of Reporting Person* <u>AH Equity Partners Bio II, L.L.C.</u> (Last) (First) (Middle) <u>C/O ANDREESSEN HOROWITZ</u> <u>2865 SAND HILL ROAD, SUITE 101</u> (City) (State) (Zip)
---	--

(Street)		
MENLO PARK	CA	94025
(City)	(State)	(Zip)

1. Name and Address of Reporting Person *

AH Bio Fund III, L.P.

(Last)

(First)

(Middle)

C/O ANDREESSEN HOROWITZ

2865 SAND HILL ROAD, SUITE 101

(Street)		
MENLO PARK	CA	94025
(City)	(State)	(Zip)

1. Name and Address of Reporting Person *

AH Equity Partners Bio III, L.L.C.

(Last)

(First)

(Middle)

C/O ANDREESSEN HOROWITZ

2865 SAND HILL ROAD, SUITE 101

(Street)		
MENLO PARK	CA	94025
(City)	(State)	(Zip)

1. Name and Address of Reporting Person *

Andreessen Marc L

(Last)

(First)

(Middle)

C/O ANDREESSEN HOROWITZ

2865 SAND HILL ROAD, SUITE 101

(Street)		
MENLO PARK	CA	94025
(City)	(State)	(Zip)

1. Name and Address of Reporting Person *

HOROWITZ BENJAMIN A

(Last)

(First)

(Middle)

C/O ANDREESSEN HOROWITZ

2865 SAND HILL ROAD, SUITE 101

(Street)		
MENLO PARK	CA	94025
(City)	(State)	(Zip)

Explanation of Responses:

1. Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
2. The reported securities are held by AH Bio Fund II, L.P. ("AH Bio Fund II"), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. ("AH EP Bio II") is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
3. The reported securities are held by AH Bio Fund III, L.P. ("AH Bio Fund III"), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, L.P. AH Equity Partners Bio III, L.L.C. ("AH EP Bio III") is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.
4. (Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

AH Bio Fund II, L.P., By AH
Equity Partners Bio II, L.L.C.,
Its General Partner, By /s/ Phil
Hathaway, Chief Operating
Officer

AH Equity Partners Bio II,
L.L.C., By /s/ Phil Hathaway,
Chief Operating Officer

AH Bio Fund III, L.P., By AH
Equity Partners Bio III, L.L.C.,
Its General Partner, By /s/ Phil
Hathaway, Chief Operating
Officer

AH Equity Partners Bio III,

07/29/2026

07/29/2026

07/29/2026

07/29/2026

<u>L.L.C., By /s/ Phil Hathaway,</u> <u>Chief Operating Officer</u>	
<u>/s/ Phil Hathaway, Attorney-in-</u> <u>Fact for Marc L. Andreessen</u>	<u>07/29/2026</u>
<u>/s/ Phil Hathaway, Attorney-in-</u> <u>Fact for Benjamin Horowitz</u>	<u>07/29/2026</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.